cardio-biochem
Terms
undefined, object
copy deck
- Describe the alternative high energy phosphate compound that serves to maintain the ATP pool.
- PHOSPHOCREATINE
- Compare the rate of ATP synthesis between Creatine Kinase and Oxidative Phosphorylation.
- ATP synthesis via Creatine Kinase is 10 times faster than from oxidative phosphorylation
- Describe the function of the Phosphocreatine Shuttle.
- Phosphocreatine Shuttle is designed to maintain the [ATP] relatively constant until the muscle nears exhaustion.ATP from mitochondria is transported to cytososol so it can be used by muscle, phosphocreatine is exchanged into mitochondria to regenerate ADP to ATP
- Describe the Phosphocreatine / ATP energy pool timeline during exercise.
- Phosphocreatine levels are rapidly depleated as they donate their phospate to sustain the ATP stores. When they are depleated the ATP stores drop and the muscle reaches exhaustion.
- Indicate the difference between Creatine and Creatinine.
- Creatinine is a breakdown product of Creatine (among other things). It has lost a H2O and is rid of by the kidneys.
- Identify the dietary and endogenous sources of Creatine.
-
Dietary = beef, fish, suppliments
Endogenous = liver - List the pros and cons of Creatine Supplementation
-
Pros: Strength, Muscle Mass, Speed
Cons: Cramps, Diarrhea, Bloating, Injuries, unknown effects of creatinine - What is the function of the Phosphocreatine Shuttle?
- Phosphocreatine Shuttle is designed to maintain the [ATP] relatively constant until the muscle nears exhaustion.
- Describe the Phosphocreatine / ATP Energy Pool timeline?
-
-- - Identify the 2 main energy sources of the heart.
- Glucose & Fatty Acids (heart prefers)
- Identify the metabolic pathway stimulated during a myocardial infarct.
- Glycolysis
- Describe the benefits of glycolysis on a hypoxic or ischemic heart.
- Glycolysis supports an hypoxic or ischemic heart. It delays progression of the ischemic contraction & increases chances that functionality will be restored upon reperfusion.
- Use Evidence Based Medicine to evaluate GIK therapy for MI patients.
- The initial trials suggested that GIK infusion might be beneficial in patients with acute coronary syndromes who were not treated with reperfusion. However, the more recent trials (GIPS-I, GIPS-II, and CREATE-ECLA) utilizing current rapid reperfusion therapies have failed to demonstrate any benefit in the administration of GIK with acute coronary syndromes.